NBE-Therapeutics is a privately-owned biotech company founded in 2012 and located in based in Basel, Switzerland.

In December 2020 NBE-Therapeutics has been acquired by Germany based private Pharma company Boehringer Ingelheim, and NBE is now a wholly owned subsidiary of Boehringer Ingelheim, Ingelheim, Germany (see this Press Release).

Prior to this acquisition, NBE-Therapeutics was financially supported by a group of institutional and private investors, led by the Boehringer Ingelheim Venture Fund (BIVF), Czech Republic’s PPF Group and Denmark’s Novo Holdings in addition to Swiss, German, and Dutch private investors. Prior to the acquisition, the company had raised over USD 65m, venture financing, and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.